However, coverage can vary by plan, so its worth checking your specific documents
Day and colleagues were the first group to use a series of modifications to the C-terminal portion of the glucagon sequence to increase GLP-1R potency, combined with PEGylation to generate two PEGylated peptides with adequate co-agonist properties, one unbalanced towards GLP-1R, and the other a near-balanced agonist at both GLP-1R and GCGR
Where appropriate, referral to a specialist Tier 3 weight-management service may also be considered
Clinical trial data from the SURMOUNT program provides robust evidence regarding expected weight loss outcomes with tirzepatide
The SGLT2i treated cohort experienced higher rates of diabetic ketoacidosis (DKA) (RR 2.08 [95% CI 1.05, 4.12] p =0.0309) and urinary tract infection/pyelonephritis (RR 2.27 [95% CI 1.12, 4.55] p =0.019) compared with the GLP-1 RA treated cohort